Harald Hefter

List of Publications by Year
in descending order

51 papers	959 citations	430754 18 h-index	454834 30 g-index
51 all docs	51 docs citations	51 times ranked	685 citing authors

#	Article	IF	Citations
1	Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure. Toxins, 2022, 14, 44.	1.5	5
2	The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formationâ€"A Monocentric Cross-Sectional Pilot Study. Medicina (Lithuania), 2022, 58, 88.	0.8	2
3	Analysis of Running in Wilsonâ€™s Disease. Sports, 2022, 10, 11.	0.7	1
4	Analysis of Single-Leg Hopping in Long-Term Treated Patients with Neurological Wilsonâ€™s Disease: A Controlled Pilot Study. Medicina (Lithuania), 2022, 58, 249.	0.8	0
5	Mildly Impaired Foot Control in Long-Term Treated Patients with Wilsonâ€™s Disease. Journal of Functional Morphology and Kinesiology, 2022, 7, 5.	1.1	3
6	Different Response Behavior to Therapeutic Approaches in Homozygotic Wilsonâ€™s Disease Twins with Clinical Phenotypic Variability: Case Report and Literature Review. Genes, 2022, 13, 1217.	1.0	3
7	The Necessity of a Locally Active Antidote in the Clinical Practice of Botulinum Neurotoxin Therapy: Short Communication. Medicina (Lithuania), 2022, 58, 935.	0.8	1
8	The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia. Journal of Neurology, 2022, 269, 5991-6002.	1.8	2
9	Longâ€term adherence and response to botulinum toxin in different indications. Annals of Clinical and Translational Neurology, 2021, 8, 15-28.	1.7	11
10	The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naÃ¯ve patients with idiopathic cervical dystonia. Journal of Neurology, 2021, 268, 206-213.	1.8	7
11	The Impact of SARS-CoV-2 Pandemic Lockdown on a Botulinum Toxin Outpatient Clinic in Germany. Toxins, 2021, 13, 101.	1.5	7
12	Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMINÂ®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins. Frontiers in Neurology, 2021, 12, 636590.	1.1	9
13	Comparing soleus injections and gastrocnemius injections of botulinum toxin for treating adult spastic foot drop: a monocentric observational study. Journal of International Medical Research, 2021, 49, 030006052199820.	0.4	2
14	Effective Treatment of Neurological Symptoms with Normal Doses of Botulinum Neurotoxin in Wilsonâ€™s Disease: Six Cases and Literature Review. Toxins, 2021, 13, 241.	1.5	6
15	Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop. Toxins, 2021, 13, 466.	1.5	2
16	The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia. Toxins, 2021, 13, 493.	1.5	3
17	The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia. Toxins, 2021, 13, 22.	1.5	6
18	Enhanced Effect of Botulinum Toxin A Injections into the Extensor Digitorum Brevis Muscle after Local Mechanical Leg Vibration: A Case Report. Toxins, 2021, 13, 423.	1.5	0

#	Article	IF	Citations
19	Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature. Toxins, 2020, 12, 499.	1.5	20
20	Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy. Frontiers in Neurology, 2020, 11, 588395.	1.1	10
21	Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 782.	1.1	6
22	Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA. Toxins, 2020, 12, 677.	1.5	3
23	Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of Treatment. Frontiers in Neurology, 2020, 11, 104.	1.1	19
24	Effective long-term treatment with incobotulinumtoxin (XeominÂ®) without neutralizing antibody induction: a monocentric, cross-sectional study. Journal of Neurology, 2020, 267, 1340-1347.	1.8	22
25	A Novel Multiple-Cue Observational Clinical Scale for Functional Evaluation of Gait After Stroke â€“ The Stroke Mobility Score (SMS). Medical Science Monitor, 2020, 26, e923147.	0.5	4
26	â€œPushing during walkingâ€•in adult patients after hemispheric stroke. Physical Medicine and Rehabilitation Research, 2020, 5, .	0.1	2
27	Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641989207.	1.5	14
28	High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology, 2019, 92, e48-e54.	1.5	95
29	Mild gait impairment in long-term treated patients with neurological Wilsonâ€™s disease. Annals of Translational Medicine, 2019, 7, S57-S57.	0.7	5
30	Long-term outcome of neurological Wilson's disease. Parkinsonism and Related Disorders, 2018, 49, 48-53.	1.1	19
31	Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study. Parkinsonism and Related Disorders, 2018, 57, 63-67.	1.1	20
32	Improvement of upper trunk posture during walking in hemiplegic patients after injections of botulinum toxin into the arm. Clinical Biomechanics, 2017, 43, 15-22.	0.5	14
33	High prevalence of neutralizing antibodies in BoNT/A long-termâ€“treated patients with focal dystonia and spasticity. Toxicon, 2016, 123, S38-S39.	0.8	1
34	Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. Journal of Neuroinflammation, 2016, 13, 278.	3.1	23
35	High Botulinum Toxinâ€Neutralizing Antibody Prevalence Under Longâ€Term Cervical Dystonia Treatment. Movement Disorders Clinical Practice, 2016, 3, 500-506.	0.8	37
36	Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: Results of the Germanâ€“Austrian open-label post-marketing surveillance prospective study. Journal of the Neurological Sciences, 2014, 337, 86-90.	0.3	29

#	Article	IF	Citations
37	Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis. Journal of Neural Transmission, 2014, 121, 513-519.	1.4	31
38	Classification of posture in poststroke upper limb spasticity. International Journal of Rehabilitation Research, 2012, 35, 227-233.	0.7	95
39	Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteinsâ€"a single cohort 4-year follow-up study. BMJ Open, 2012, 2, e000646.	0.8	47
40	Impact of posterior deep neck muscle treatment on cervical dystonia: Necessity to differentiate between abnormal positions of head and neck. Basal Ganglia, 2012, 2, 103-107.	0.3	7
41	A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis. BMJ Open, 2011, 1, e000196-e000196.	0.8	29
42	Evaluation of the Symptomatic Treatment of Residual Neurological Symptoms in Wilson Disease. European Neurology, 2010, 64, 83-87.	0.6	38
43	Coordination between breathing and forearm movements during sinusoidal tracking. European Journal of Applied Physiology, 2000, 81, 288-296.	1.2	41
44	Stavudine and the peripheral nerve in HIV-1 infected patients. Journal of Neurology, 1999, 246, 211-217.	1.8	9
45	His1069Gln and six novel Wilson disease mutations: analysis of relevance for early diagnosis and phenotype. European Journal of Human Genetics, 1998, 6, 616-623.	1.4	56
46	Neurological impairment and recovery in Wilson's disease: evidence from PET and MRI. Journal of the Neurological Sciences, 1996, 136, 129-139.	0.3	57
47	Focal brain lesions in patients with AIDS: Aetiologies and corresponding radiological patterns in a prospective study. Journal of Neurology, 1995, 242, 69-74.	1.8	21
48	WilsonÊ¼s Disease. CNS Drugs, 1994, 2, 26-39.	2.7	6
49	Electrophysiological motor testing, MRI findings and clinical course in AIDS patients with dementia. Journal of Neurology, 1993, 240, 439-445.	1.8	21
50	Does tremor pace repetitive voluntary motor behavior in parkinson's disease?. Annals of Neurology, 1991, 30, 172-179.	2.8	88
51	Clinical Relevance of Neutralizing Antibodies in Botulinum Neurotoxin Type A. , 0, , .		0